Top

Published in:

01-06-2005

Prognostic Value of MIB-1, E-Cadherin, and CD44 in Pediatric Chordomas

Authors: Aly G. Saad, Margaret H. Collins

Published in: Pediatric and Developmental Pathology | Issue 3/2005

Abstract

The prognosis of pediatric chordomas is difficult to predict based on histology. The objective of this study was to assess the expression of a proliferation marker and adhesion molecules in pediatric chordomas and relate the expressions to outcome. In 8 pediatric chordomas, we calculated the MIB-1 labeling index (LI) by counting the number of MIB-1–positive tumor cells in 100 tumor cells. The grade of expression of E-cadherin and CD44 was calculated by estimating the percentage of tumor cells expressing these markers. MIB-1 LI correlated with tumor recurrence (P = 0.007) and low survival rate (P = 0.007). The expression of E-cadherin correlated with disease-free survival (P = 0.009), tumor recurrence (P > 0.0007), and low survival rate (P > 0.0007). CD44 expression did not correlate with recurrence (P = 0.056) or survival rate (P = 0.056). Our results suggest that MIB-1 LI and expression of E-cadherin are helpful to predict outcome in pediatric chordomas.

Sibley RK, Day DL, Dehner LP. Metastasizing chordoma: a pathological and immunohistochemical study with review of the literature. Pediatr Pathol 1987;7:287–301PubMed

Abenoza P, Sibley RK. Chordoma: an immunohistological study. Hum Pathol 1986;17:744–747PubMedCrossRef

Miettinen M. Chordoma. Antibodies to epithelial membrane antigen and carcinoembryonic antigen in differential diagnosis. Arch Pathol Lab Med 1984;108:891–924PubMed

Horiguchi H, Sano T, Qian ZR, et al. Expression of cell adhesion molecules in chordomas: an immunohistochemical study of 16 cases. Acta Neuropathol 2004;107:91–96PubMedCrossRef

Mori K, Chano T, Kushima R, Hukuda S, Okabe H. Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity. Virchows Arch 2002;440:123–127PubMedCrossRef

Rutherfoord GS, Davies AG. Chordomas—ultrastructure and immunohistochemistry: a report based on the examination of six cases. Histopathology 1987;11:775–787PubMedCrossRef

Miettinen M, Lehto VP, Dahl D, Virtanen I. Differential diagnosis of chordoma, chondroid, an ependymal tumors as aided by anti-intermediate filaments antibodies. Am J Pathol 1983;112:160–169PubMedPubMedCentral

Naka T, Oda Y, Iwamoto Y, Shinohara N, Chuman H, Fukui M, Tsuneyoshi M. Immunohistochemical analysis of E-cadherin, alpha-catenin, and neural cell adhesion molecules (NCAM) in chordoma. J Clin Pathol 2001;54:945–950PubMedPubMedCentralCrossRef

Gotz G, Kasper M, Fisher G, Herken R. Intermediate filament typing of the human embryonic and fetal notochord. Cell Tissue Res 1995;280:455–462PubMedCrossRef

10.

Takeichi M. cadherin cell adhesion receptor as a morphologic regulator. Science 1991;251:1451–1455PubMedCrossRef

11.

Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989;108:2435–2447PubMedCrossRef

12.

Fahraeus R, Chen W, Trivedi P, Klein G, Obrink B. Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. Int J Cancer 1992;52:834–838PubMedCrossRef

13.

Laskin WB, Miettinen M. Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues. Arch Pathol Lab Med 2002;126:425–431PubMedCrossRef

14.

Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527–579PubMedCrossRef

15.

Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277:4589–4592PubMedCrossRef

16.

Guler G, Sarac S, Uner, Karabulut E, Ayhan A, Ogawa H. Prognostic value of CD44 variant 6 in laryngeal epidermoid carcinomas. Arc Otolaryngol Head Neck Surg 2002;128:393–397CrossRef

17.

Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop 2002;396:184–190CrossRef

18.

Kawasaki H, Toyada M, Shinohara H, et al. Expression of surviving correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001;91:2026–2032PubMedCrossRef

19.

Ali-Fehmi R, Qureshi F, Lawrence WD, Jacques SM. Apoptosis, proliferation, and expression of p53 and bcl-2 in endocervical glandular intraepithelial lesions and invasive endocervical adenocarcinoma. Int J Gynecol Pathol 2004;23:1–6PubMedCrossRef

20.

Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1 and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004;45:606–612PubMedCrossRef

21.

Staibano S, Franco R, Tranfa F, et al. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and li67 (MIB1) expression and clinical behavior. Anticancer Res 2004;24:249–257PubMed

22.

Roggendorf W, Schuster T, Peiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol 1987;73:361–364PubMedCrossRef

23.

Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002;94:1538–1547PubMedCrossRef

24.

Hoyt JW, Grown AM, Kim DK, Berger MS. Analysis of proliferative grade in glial neoplasm using antibodies to the Ki-67 antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 1995;24:163–169PubMedCrossRef

25.

Frank I, Cheville JC, Blute ML, et al. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 2004;101:1803–1808PubMedCrossRef

26.

Kilgore S, Prayson RA. Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol 2002;6:222–228PubMedCrossRef

27.

Holton JL, Steel T, Luxsuwong M, Crockard HA, Revesz T. Skull base chordomas: correlation to tumour doubling time with age, mitosis and Ki67 proliferation index. Neuropathol Apl Neurobiol 2000;26:497–503CrossRef

28.

Naka T, Boltze C, Samii A, et al. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer 2003;98:1934–1941PubMedCrossRef

29.

Matsuno A, Sasaki T, Nagashima T, et al. Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomas. Hum Pathol 1997;28:714–719PubMedCrossRef

30.

Ariel IM, Verdu C. Chordoma: an analysis of twenty cases treated over a twenty-year span. J Surg Oncol 1975;7:27–44PubMedCrossRef

31.

Congdon CC. Benign and malignant chordomas. A clinicoanatomic study of twenty-two cases. Am J Pathol 1952;28:793–821

32.

Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and cartilaginous tumors at the skull base. Cancer 1973;23:410–420CrossRef

33.

Higinbotham NL, Phillips RF, Farr HW, Hustsu HO. Chordoma. Thirty-five–year study at Memorial Hospital. Cancer 1967;11:1841–1850

34.

Kaneko Y, Sato Y, Iwaki T, Shin RW, Tateishi J, Fukui M. Chordoma in early childhood: a clinicopathological study. Neurosurgery 1991;29:442–446PubMedCrossRef

35.

Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the chromosme and morphology (CHAMP) collaborative study group. J Pathol 2002;196:194–203

36.

Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002

37.

Scheil S, Bruderlein S, Liehr T, et al. Genome-wide analysis of 16 chordomas by comparative genomic hybridization and cytogenetics of the first human chordomas cell line, U-CH1. Genes Chromosomes Cancer 2001;32:203–211PubMedCrossRef

38.

Gil Z, Fliss DM, Voskoboinik N, et al. Cytogenetic analysis of three variants of clival chordoma. Cancer Genet Cytogenet 2004;154:124–130PubMedCrossRef

39.

Hruban RH, Traganos F, Reuter VE, Huvos AG. Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications. Am J Pathol 1990;137:435–447PubMed

40.

Spaar FW, Spaar U, Markakis E. DNA in chordomas of the clivus Blumenbachii. Neurosurg Rev 1990;13:219–229PubMedCrossRef

41.

Berven S, Zurakowski D, Mankin HJ, Gebhardt MC, Springfield DS, Hornicek FJ. Clinical outcome in chordoma: utility of flow cytometry in DNA determination. Spine 2002;27:374–379PubMedCrossRef

42.

Ammirati M, Bernardo A. Management of skull base chordoma. Crit Rev Neurosurg 1999;9:63–69PubMedCrossRef

43.

Gay E, Sekhar LN, Rubinstein E, et al. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 1995;36:887–896PubMedCrossRef

44.

Chambers PW, Schwinn CP. Chordoma: a clinicopathologic study of metastasis. Am J Anat 1979;128:193–224

45.

Forsyth PA, Cascino T, Shaw EG, et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993;78:741–747PubMedCrossRef

46.

Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999;91:432–439PubMedCrossRef

Title: Prognostic Value of MIB-1, E-Cadherin, and CD44 in Pediatric Chordomas
Authors: Aly G. Saad
Margaret H. Collins
Publication date: 01-06-2005
Publisher: Springer New York
Published in: Pediatric and Developmental Pathology / Issue 3/2005
Print ISSN: 1093-5266
Electronic ISSN: 1615-5742
DOI: https://doi.org/10.1007/s10024-005-1127-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic Value of MIB-1, E-Cadherin, and CD44 in Pediatric Chordomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2005

Tribute to Laurence Edward Becker, MD, FRCPC (March 30, 1943, to July 14, 2002)

In Situ Neuroblastoma: An Important Concept Related to the Natural History of Neural Crest Tumors

J. Bruce Beckwith—Physician Scientist

Book Reviews

ANNOUNCEMENTS

Introduction